Research analyst, medium-term horizon, biotech, small-cap

Scientific Literature Suggests Amarantus' MANF Has Big Potential

By Jason Napodano, CFA

We have reviewed twenty scientific papers in an attempt to better understand the mechanism of action, preclinical data, and the commercial potential for Amarantus Biosciences' (OTCQB:AMBS) Mesencephalic Astrocyte-Derived Neurotrophic Factor (OTC:MANF). Below is a review of those papers, in chronological order from the date they were first published.

Paper # 1 - Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW. (April 2003) MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons. Journal of Molecular Neuroscience, Vol.20/2:173-187.

The Petrova et al. paper above was the first characterization we found on MANF. Petrova et...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details